Charles Hooper - Apr 14, 2023 - Winnipeg, Manitoba

Charles Hooper worked for Merck when Ivermectin was first released. He explains that in a pandemic, repurposed drugs are important due to the long timeline for development of new drugs. Charles decided to study Ivermectin at the beginning of the pandemic. He reanalyzed 95 clinical studies involving 27 countries and 134,554 patients confirming decreased death (51%), mechanical ventilation, ICU admission and improved recovery.

For the complete witness testimony, transcript, exhibits and more, please visit https://nationalcitizensinquiry.ca/witness/charles-hooper

Testimony Code: 2304WPG210